EXP016

EXP016 is a tri-specific antibody being developed by Excalipoint, a China-based biotechnology startup backed by Eli Lilly, for the treatment of solid tumors. As a next-generation T-cell engager (TCE), EXP016 is engineered using the company's proprietary TOPAbody technology platform, which facilitates the generation of tri-specific molecules. The drug also incorporates Excalipoint's T-Cell Immune Shield and TCE Probody technologies, which are designed to enhance the therapeutic window by improving safety and specificity. While the specific molecular targets of EXP016 have not been publicly disclosed, the candidate is intended to address high unmet needs in oncology and was highlighted as part of the company's $68.7 million seed funding round in March 2026.